ライフサイエンスコーパス: Japanese patient

1 and a severe thrombotic phenotype in a young Japanese patient.

2 dominantly inherited DRD and in one sporadic Japanese patient.

3 CV-induced hepatocellular carcinoma (HCC) in Japanese patients.

4 ) of GUCA1A-associated IRDs may be low among Japanese patients.

5 as well as American, Canadian, European, and Japanese patients.

6 olangiocarcinomas and gallbladder cancers in Japanese patients.

7 treatment of genotype 1 hepatitis C virus in Japanese patients.

8 ata suggest its association with glaucoma in Japanese patients.

9 eported survival benefit observed with IP in Japanese patients.

10 with HTLV-1 that have not been described in Japanese patients.

11 We studied 117 H. pylori-infected Japanese patients.

12 ions (MOCP), we analysed 100 lesions from 26 Japanese patients.

13 y linked to hepatocellular carcinogenesis in Japanese patients.

14 in NEUROG3 are not a common cause of MODY in Japanese patients.

15 nts undergoing hemodialysis than Swedish and Japanese patients.

16 were better in white compared with black and Japanese patients.

17 lymorphisms of DLST and AD in both white and Japanese patients.

18 repeat number observed in the C/C homozygous Japanese patients.

19 way, was found to cause this disease in some Japanese patients.

20 patients closely resemble those described in Japanese patients.

21 ths, compared to 117 (IQR 30-146) months for Japanese patients.

22 Filipino patients, 76 Hispanic patients, 107 Japanese patients, 10 Korean patients, 299 Native Hawaii

23 The previous report on the Japanese patients also suggested that disease allele sta

24 al correlation in a population including 985 Japanese patients and staff members of an ophthalmology

25 in a training set of tissue samples from 82 Japanese patients, and the signature was validated in ti

26 DRD) was originally described in a series of Japanese patients, but is now increasingly recognized in

27 been obtained through studies of Jewish and Japanese patient cohorts carrying founder mutations in t

28 ive and specific for the diagnosis of HCC in Japanese patients compared with alpha-fetoprotein (AFP).

29 We investigated two Japanese patients diagnosed with severe, chronic active

30 en at a dose of 300 mg once a day (200 mg in Japanese patients) for 14 days in a 28-day cycle or gemc

31 However, Japanese patients had a lower annualised relapse rate (0

32 We found that Japanese patients had a lower risk of subsequent attacks

33 Only 0.3% of German and Japanese patients had advance directives, and such direc

34 5 cagA gene-positive H. pylori isolates from Japanese patients including 50 patients with simple gast

35 pitopes in the immunogens in treatment-naive Japanese patients infected with HIV-1 clade B.

36 missense mutation (R242H) of GRTH in 5.8% of Japanese patient population with azoospermia.

37 to the carboxyl terminus of topo I, sera of Japanese patients preferentially recognized the portion

38 In part 2, six Japanese patients received the felzartamab 9-dose schedu

39 roportion of European, African-American, and Japanese patients specifically reacted with the sumoylat

40 A recent report studying Japanese patients suggested that a polymorphism of a tri

41 ion of a novel DNA virus from the serum of a Japanese patient (T.T.) has provided the latest possible

42 i-topo I antibody more frequently in sera of Japanese patients than in sera of white patients.

43 ative for HLA-DQA1*0501 and *0401, including Japanese patients, the HLA-DQA1*0102 and *0103 alleles p

44 cates that the increased sensitivity of some Japanese patients to thiopurines may reflect the greater

45 serum samples from 109 U.S. patients and 288 Japanese patients using enzyme immunoassay with differen

46 I, 1.02-7.14; P = .04), when mortality among Japanese patients was lowest (OR, 0.19; 95% CI, 0.03-0.7

47 Moreover, in another Japanese patient, we identified a homozygous frameshift

48 In a genomic screen of 331 unrelated Japanese patients, we identify a disruptive Alu insertio

49 Japanese patients were more commonly treated with long-t

50 variants were found within this region in 61 Japanese patients, which could contribute to the pathoge

51 ated in tissue sections taken from 18 US and Japanese patients who died of acute KD and from 10 age-m

52 Sixty Japanese patients who visited the Department of Orthodon

53 In this retrospective study, data from 640 Japanese patients who were treated for chronic hepatitis

54 We followed 215 Japanese patients with acute HBV infection until the cle

55 as a first-line treatment were evaluated in Japanese patients with advanced gastric or gastroesophag

56 inistration is safe and clinically useful in Japanese patients with AHP.

57 rther explored its safety and efficacy in 10 Japanese patients with AHP.

58 ks in treatment-naive and previously treated Japanese patients with chronic genotype 1 hepatitis C vi

59 es of beta-CAS and alphas-CAS are similar in Japanese patients with CMA.

60 requency of anti-Fibrillin-1 was observed in Japanese patients with diffuse and limited scleroderma o

61 followed by two validation studies, in 3,173 Japanese patients with EGFR mutation-positive lung adeno

62 rvival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung c

63 as recently detected with high prevalence in Japanese patients with fulminant hepatitis and chronic l

64 , single-arm, Phase 3 study was conducted in Japanese patients with HAE (NCT02865720).

65 ety signals identified in this population of Japanese patients with HAE.

66 gh attacks with favourable safety profile in Japanese patients with HAE.

67 ociated with SSc in both Native American and Japanese patients with limited scleroderma.

68 Ninety-six Japanese patients with major depressive disorder were tr

69 red FABA/ICS is a useful treatment option in Japanese patients with mild asthma.

70 16 of the RET proto-oncogene in 33 unrelated Japanese patients with MTC.

71 an unusually high frequency in this group of Japanese patients with myositis.

72 9 Filipino, 90 Ethiopian, 90 Nigerian and 95 Japanese patients with nsCL/P and identified three rare

73 at suggest high risk of the disorder, and 12 Japanese patients with optic-spinal multiple sclerosis.

74 We enrolled 77 Japanese patients with OSA who underwent simultaneous ty

75 Sera from 36 Japanese patients with PM/DM (13 with PM, 20 with DM, 3

76 ical associations of these autoantibodies in Japanese patients with PM/DM were investigated.

77 sis of the phase III trial of rupatadine for Japanese patients with pruritus associated with skin dis

78 of lenalidomide, an oral immunomodulator, in Japanese patients with relapsed adult T-cell leukaemia-l

79 e exome sequencing of 18 trios consisting of Japanese patients with sporadic schizophrenia and their

80 ngle nucleotide polymorphisms (SNPs) in 8880 Japanese patients with type 2 diabetes, 4839 retinopathy

81 d 4041 controls, as well as 2217 independent Japanese patients with type 2 diabetes, 693 retinopathy

82 ility to diabetic retinopathy in Chinese and Japanese patients with type 2 diabetes.

83 er susceptibility to diabetic retinopathy in Japanese patients with type 2 diabetes.